EP1. 16-17 Management of Inappropriate Use of Opioids (IUO) in Patients (P) with Lung Cancer (LC)

Pain represents one of the main symptoms in patients (p) with lung cancer (LC). Currently, the molecular classification and targeted therapies and immunotherapy for LCp yield a prolonged survival in some p. In this context, analgesia with opioid therapy (OT) requires special caution. The prevalence of IUO LCp is unknown and its assessment is suboptimal. There is no current recommendation to assess IUO risk in cancer p, other than in long cancer survivors with chronic pain. Several scales are validated for the screening of aberrant OT-behaviors. The Addiction Unit (AU) role could be key in the evaluation and minimization of the IUO risk (Fig.1) STUDY DESIGN: Prospective study for the evaluation of IUO risk in LCp. P with intermediate/high risk of IUO will be referred to the AU for evaluation and follow-up (Fig.1) OBJECTIVES: Determine if screening scales are capable of detecting the risk of IUO in LCp. Reduce the impact of IUO in LCp by assessment and follow-up in the AU. VARIABLES: Main: To determine if the Cut down-Annoyed-Guilty-Eye opener (CAGE-AD) and Opioid Risk Tool (ORT) scales are able of detecting the risk of IUO in LCp. Secondary: Determine if the urine and blood drug testing (DT) reinforces the information of such scales. Determine the risk reduction of IUO after the intervention of the AU.